NovoCure (NVCR) Total Debt Growth (3y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | 26.30% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 4.07% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -0.07% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 6.99% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 0.11% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 1.72% |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | - |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -0.34% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | -14.39% |
| 10 | NovoCure | 1.90 Bn | 1.47 Bn | 135.13 Mn | -29.85% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -29.85% |
| Dec 31, 2025 | -29.87% |
| Sep 30, 2025 | -29.89% |
| Jun 30, 2025 | -44.27% |
| Mar 31, 2025 | -44.27% |
| Dec 31, 2024 | -44.27% |
| Sep 30, 2024 | -44.27% |
| Jun 30, 2024 | -44.28% |
| Mar 31, 2024 | 0.60% |
| Jun 30, 2023 | 55.96% |
| Mar 31, 2023 | 55.90% |
| Dec 31, 2022 | 55.84% |
| Sep 30, 2022 | 55.78% |
| Jun 30, 2022 | 55.71% |
| Mar 31, 2022 | 55.65% |
| Dec 31, 2021 | 55.59% |
| Sep 30, 2021 | 55.53% |
| Jun 30, 2021 | 55.46% |
| Mar 31, 2021 | 55.38% |
| Dec 31, 2020 | 64.07% |
| Jun 30, 2020 | 15.61% |
| Mar 31, 2020 | 15.70% |
| Dec 31, 2019 | 15.80% |
| Sep 30, 2019 | 15.89% |
| Jun 30, 2019 | 85.78% |
| Mar 31, 2019 | 86.03% |
| Dec 31, 2018 | 944.48% |
| Sep 30, 2018 | 82.49% |